Karyopharm Therapeutics Stock Target Price and Analyst Consensus
| KPTI Stock | USD 1.17 0.11 8.59% |
The current analyst and expert consensus on Karyopharm Therapeutics is Strong Buy, with 2 strong buy opinions. The current projected Karyopharm Therapeutics target price consensus is 6.67 with 7 analyst opinions. The most common way Karyopharm Therapeutics analysts use to provide recommendation to the public is financial statements analysis. Many experts also interview Karyopharm Therapeutics executives and customers to further validate their buy or sell advice. Note, the total number of analysts currently providing their opinion is not significant to determine adequate consensus on Karyopharm Therapeutics. We strongly encourage you to use your own analysis of Karyopharm Therapeutics to validate this buy or sell advice. Karyopharm Therapeutics buy-or-sell recommendation module provides average expert sentiment on the projected Karyopharm Therapeutics target price to derive its highest and lowest estimates based on its projected price volatility. Check out Macroaxis Advice on Karyopharm Therapeutics to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.
Lowest Forecast 6.07 | Highest Forecast 7.4 | Target Price 6.67 |
Karyopharm |
It's important to approach Karyopharm Therapeutics' target price projections with caution. While they can be useful as part of a broader investment strategy, they are inherently speculative and subject to various kinds of risk, including market volatility and unforeseen external factors. Always consider multiple aspects and do your own research when making investment decisions.
Analysts determine stock price targets through various methods, including financial modeling, peer comparison, and company analysis. The stock price target is the analyst's best estimate of the future price of a stock and is used by investors to make investment decisions. However, it is important to note that stock price targets are not guaranteed, and the actual price of a stock can differ significantly from the target due to various factors such as market conditions, economic events, and company developments.
Steps to utilize Karyopharm Therapeutics price targets
Karyopharm Therapeutics' stock target price is an estimate of its future price, usually made by analysts. Using Karyopharm Therapeutics' target price to determine if it is a suitable investment can be done through the following steps:- Look at Karyopharm Therapeutics' target prices provided by various analysts and compare them. This can help you gain a more balanced view of the Stock's potential.
- Look at the analyst's track record to determine if they have a history of accurately predicting stock prices.
- Look at the Company's financials, including revenue, earnings, and debt, to determine if it is in good financial health.
- Consider market conditions. For example, take into account the state of the economy, competition, and regulatory environment, to determine if Karyopharm Therapeutics' stock is likely to perform well.
- Diversify your portfolio and do not rely solely on stock target prices to make investment decisions. Invest in a mix of stocks, bonds, and other assets to manage risk.
Additional Karyopharm Therapeutics Value Projection Modules
Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of Karyopharm Therapeutics is a key component of Karyopharm Therapeutics valuation and have some predictive power on the future returns of a Karyopharm Therapeutics.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Karyopharm Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Warren Buffett Holdings Invested over 70 shares | |
 | Manufacturing Invested over 40 shares | |
 | Momentum Invested over 200 shares | |
 | Banking Invested over 30 shares | |
 | Social Domain Invested few shares | |
Check out Macroaxis Advice on Karyopharm Therapeutics to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Complementary Tools for Karyopharm Stock analysis
When running Karyopharm Therapeutics' price analysis, check to measure Karyopharm Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Karyopharm Therapeutics is operating at the current time. Most of Karyopharm Therapeutics' value examination focuses on studying past and present price action to predict the probability of Karyopharm Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Karyopharm Therapeutics' price. Additionally, you may evaluate how the addition of Karyopharm Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |
The data published in Karyopharm Therapeutics' official financial statements usually reflect Karyopharm Therapeutics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Karyopharm Therapeutics. For example, before you start analyzing numbers published by Karyopharm accountants, it's critical to develop an understanding of what Karyopharm Therapeutics' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Karyopharm Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Karyopharm Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Karyopharm Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Karyopharm Therapeutics. Please utilize our Beneish M Score to check the likelihood of Karyopharm Therapeutics' management manipulating its earnings.